Description
Tirzepatide for Weight Loss is a dual insulinotropic receptor agonist with both strong glucose-lowering and significant weight-loss capabilities, characterized by a low inherent risk of hypoglycemia and multiple cardiometabolic benefits. Proper initiation and escalation, attention to gastrointestinal tolerance, and adjustments to concurrent medications are crucial for its clinical application. In weight management settings, long-term maintenance therapy combined with lifestyle modifications is typically required to consolidate therapeutic effects and reduce weight rebound.
As one of the top five tirzepatide producers in China, Shaanxi Medibridge can provide tirzepatide with a purity of 99.988%, while the purity of typical laboratories can only reach 99.4%. Some smaller, illegal laboratories even produce tirzepatide with a purity of less than 98%.
COA
|
Item |
Standard |
Results |
|
Purity |
≥98% |
99.986% |
|
Peptide Assay |
≥80% |
95.12% |
|
Mass Spectrum |
4813.45 ± 0.5 |
4813.21 |
|
Sequence |
Tyr-{Aib}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr- Ser-Ile-{Aib}-Leu-Asp-Lys-Ile-Ala-Gln-{diacid- gamma-Glu-(AEEA)2-Lys}-Ala-Phe-Val-Gln- Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 |
Matches |
|
Appearance |
White fine powder |
Complies |
|
Solubility |
Soluble in water |
Complies |
|
Clarity and color of solution |
Clear and colorless |
Complies |
|
PH |
6.0 – 9.0 |
7.74 |
|
Sodium ion |
≤3.0% |
1.33% |
|
Water |
≤10.0% |
1.09% |
|
Residual Solvent: Methanol Isopropanol Acetonitrile Methylene Chloride N,N-Dimethylformamide Triethylamine Tert-butyl methyl ether |
||
|
≤0.3% |
0.0066% |
|
|
≤0.5% |
N.D. |
|
|
≤0.041% |
0.019% |
|
|
≤0.06% |
0.028% |
|
|
≤0.088% |
N.D. |
|
|
≤0.032% |
N.D. |
|
|
≤0.5% |
0.130% |
|
|
Endotoxin |
≤5 EU/mg |
0.08 EU/mg |
|
Microbial Limit |
Total aerobic bacteria <100 CFU/g Total yeast & mold <50 CFU/g |
<50 CFU/g <10 CFU/g |
|
Storage |
Keep in dark and cool dry place (-20 to 8°C) |
|
|
|
||
Specifications (for research use only)
|
Form |
Sample Order |
Specification |
|
Raw powder |
1 g |
Purity is NLT 99.96% |
|
Vials |
10 vials |
3ml/5ml/7ml/15ml vials etc. |
Scientific Progress
Cardiovascular Outcomes Overview
Tirzepatide Cardiovascular Outcomes Overview (SURPASS‑CVOT) This figure summarizes the primary and key secondary findings from SURPASS‑CVOT. Tirzepatide met noninferiority versus dulaglutide for MACE‑3 (HR 0.92; CI includes 1.0), with a significant reduction observed in all‑cause mortality (HR 0.84). Components of MACE‑3 include cardiovascular death, nonfatal MI, and nonfatal stroke. Interpretation is research‑oriented: secondary signals are hypothesis‑generating and should be contextualized with full trial methods and statistical hierarchies. For research visualization only.
Pharmacokinetics: Half‑Life and Weekly Dosing Rhythm
This schematic illustrates tirzepatide's PK profile supporting once‑weekly subcutaneous administration. The approximate half‑life of ~5 days and albumin binding underpin sustained exposure across the dosing interval and steady‑state attainment in roughly four weeks. The curve is illustrative (not to scale) and intended to convey the dosing rhythm rather than exact concentrations. Use for academic discussion of sampling windows, model‑informed dosing, and exposure–response planning. For research visualization only; not for clinical decision‑making.
Cardiometabolic Profile: Biomarkers in SURPASS
Biomarkers in SURPASS This panel highlights multidimensional risk‑factor modification observed across SURPASS trials. Reductions in HbA1c (up to ~−2.4%), body weight, systolic blood pressure, and triglycerides, with favorable changes in HDL and albuminuria, align mechanistically with cardiometabolic risk reduction. Effect sizes vary by dose, population, and study design; figures are illustrative and not pooled estimates. Interpret biomarker shifts as supportive context rather than proof of cardiovascular event reduction. For research visualization only.
PK: Multi-Dose Accumulation to Steady State
The multi‑dose PK graphic shows peak–trough profiles with weekly injections and progressive accumulation toward steady‑state by approximately Week 4. Annotations of t1/2 (~5 days), Cmax, and Ctrough emphasize exposure maintenance across the interdose interval. Such profiles are useful for planning PK/PD sampling, nonlinear mixed‑effects modeling, and understanding concentration‑dependent tolerability. Curve shape and magnitudes are schematic and not to scale. For research visualization only; not for clinical decision‑making.
Research Direction
Tirzepatide for Weight Loss is a dual GIP/GLP‑1 receptor agonist that produces sustained, dose‑dependent weight reduction (~15–21% at 72 weeks in adults without diabetes) alongside improvements in cardiometabolic markers. Key research directions include predictors of response and tolerability (biomarkers, phenotypes), strategies for maintenance and adherence, mechanistic links to visceral adiposity and hepatic steatosis, and long‑term comparative effectiveness and safety versus other incretin therapies.
Worry-free After-sales Service
As a highly influential peptide supplier, Shaanxi Medibridge not only provides high-quality, high-purity Tirzepatide, but also supports testing for every order placed by both new and existing clients. Each batch of our peptide products comes with a Certificate of Authorization (COA) issued by our laboratory. If the quality fails to meet standards, we will bear all losses (including but not limited to shipping costs, product costs, testing fees, etc.).
Furthermore, Shaanxi Medibridge also supports custom orders for raw powder in kilogram quantities. We also support custom orders for any vials intended solely for research use.
FAQ
Q: Can the product purity reach 99%?
A: We fully guarantee the purity of our products to be above 99.98% and support Chromate and Janoshik testing.
Q: Can you guarantee sufficient peptide content?
A: Of course. Sometimes, due to incomplete dissolution of the Vials product during retesting, there may be a slight error in the peptide content of the retest results, generally around ±0.5mg.
Q: Do you have endotoxin control?
A: Of course. We also support customers in providing additional testing for endotoxins/heavy metals, etc.
Q: Shipping and storage requirements?
A: We will ship via FedEx/UPS/DHL. After arrival, the product needs to be stored at −20°C, protected from light and in a dry place, avoiding repeated freeze-thaw cycles as much as possible.
Q: Reconstitution and usage recommendations?
A: Pre-dissolve in sterile water or PBS; if necessary, add 0.1–1% HSA/BSA to reduce adsorption; filter at 0.22 μm as needed; store at −20°C after aliquoting.
Q: Delivery time, order quantity, and price?
A: In-stock items ship within 2 business days; bulk pricing is negotiable.
Q: Scope of application and compliance?
A: For research use only (RUO). Strictly prohibited for human diagnosis and treatment. If non-compliance is discovered, we reserve the right to refund and refuse to ship the order.
Currently, Tirzepatide for Weight Loss is indeed a very promising area of research in blood glucose control. If you are currently looking for a high-quality peptide manufacturer with whom you can have a long-term, stable partnership, please contact us at hi@medibridgeapi.com.
Hot Tags: tirzepatide for weight loss, China tirzepatide for weight loss manufacturers, suppliers, factory, ARA 290 Powder, Dermorphin Peptide, Epithalon Powder, Peptide SS 31, peptides, Selank Powder
